These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30721710)

  • 21. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
    Suri A; Mould DR; Song G; Kinley J; Venkatakrishnan K
    J Clin Pharmacol; 2020 Dec; 60(12):1585-1597. PubMed ID: 32596842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.
    Wang K; Jiang K; Wei X; Li Y; Wang T; Song Y
    AAPS PharmSciTech; 2021 Jul; 22(6):208. PubMed ID: 34312742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.
    Hornik CP; Wu H; Edginton AN; Watt K; Cohen-Wolkowiez M; Gonzalez D
    Clin Pharmacokinet; 2017 Nov; 56(11):1343-1353. PubMed ID: 28290120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin.
    Willmann S; Frei M; Sutter G; Coboeken K; Wendl T; Eissing T; Lippert J; Stass H
    CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):654-663. PubMed ID: 31310051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations.
    Wu X; Zhang H; Miah MK; Caritis SN; Venkataramanan R
    J Clin Pharmacol; 2020 Apr; 60(4):477-488. PubMed ID: 31750550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Pediatric Rectal Absorption, Drug Disposition, and Sedation Level for Midazolam Gel Using Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.
    Zhu J; Zhou S; Wang L; Zhao Y; Wang J; Zhao T; Li T; Shao F
    Mol Pharm; 2024 May; 21(5):2187-2197. PubMed ID: 38551309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form.
    Purohit V; Sagawa K; Hsu HJ; Kushner J; Dowty ME; Tse S; Lin J; Blanchard A; Mukherjee A; Le V; Chang C
    Clin Pharmacol Ther; 2024 Oct; 116(4):996-1004. PubMed ID: 38797995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.
    Maharaj AR; Barrett JS; Edginton AN
    AAPS J; 2013 Apr; 15(2):455-64. PubMed ID: 23344790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model.
    Rashid M; Sarfraz M; Arafat M; Hussain A; Abbas N; Sadiq MW; Rasool MF; Bukhari NI
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):56. PubMed ID: 32727574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
    Conner TM; Reed RC; Zhang T
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects.
    Matsumoto Y; Cabalu T; Sandhu P; Hartmann G; Iwasa T; Yoshitsugu H; Gibson C; Uemura N
    Clin Pharmacol Ther; 2019 Apr; 105(4):1018-1030. PubMed ID: 30252941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague.
    Nguyen D; Shaik JS; Tai G; Tiffany C; Perry C; Dumont E; Gardiner D; Barth A; Singh R; Hossain M
    Br J Clin Pharmacol; 2022 Feb; 88(2):416-428. PubMed ID: 34289143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.